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1. Introduction 
Posttraumatic stress disorder (PTSD) is a chronic and disabling anxiety disorder that occurs 
after a traumatic event. In this chapter, we will briefly discuss current research in concept, 
diagnosis and treatment strategies of PTSD. In addition, we will introduce the concept of 
biomarkers for PTSD. In each section, we will focus on the discussion of current 
translational research in PTSD, including clinical and molecular studies in PTSD. 
Specifically, we will discuss the strategies of translational studies, from bench to bedside 
and from bedside to bench, two research approaches in the development or identification of 
PTSD biomarker, a novel approach to diagnosis and treatment. Recent data from the 
national co-morbidity survey indicates PTSD prevalence rates are 5% and 10% respectively 
among American men and women. The prevalence of PTSD in the military population is 
much higher from 10% to 30%. 
2. Concept of PTSD 
PTSD is a type of anxiety disorders. Its onset may occur soon after a major trauma, or be 
delayed by more than 6 months after the event. When PTSD occurs, it usually gets better 
after 3 months. However, some people will suffer chronically from PTSD, lasting for many 
years. PTSD can occur at any age and can follow a natural disaster such as a flood or fire, or 
events such as war, a prison stay, assault, domestic abuse, and/or rape. The terrorist attacks 
of September 11, 2001, for example, caused PTSD in people who were involved, witnessed 
the disaster, or lost relatives and friends. PTSD can also occur in military service members 
during war, such as the Iraq war. These traumatic events can produce stress in all involved, 
but less than 30% of those involved develop PTSD. PTSD patients exhibit depressive 
symptoms, abnormality of the circulating levels of the stress hormones and 
neurotransmitter activity, and alteration of gene expression. PTSD symptoms have been 
around for long time. The significance of PTSD came to public attention only recently. 
3. Historical changes in the concept of PTSD in diagnosis  
Throughout our history, PTSD has been called a number of other different names. It was 
called soldier's heart for soldiers who developed the symptoms of PTSD after the Civil War 
and combat fatigue or shell shock for soldiers after World War I. During the World War II, it 
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was called battle fatigue or gross stress. PTSD was recognized as one of mental disorders by 
the American Psychiatric Association (APA) officially and was added to the Diagnostic 
Manual of Mental Disorders (DSM), in 1980s. The DSM-III diagnostic criteria for PTSD were 
revised in DSM-III-R (1987) and DSM-IV (1994). A very similar syndrome is classified in 
ICD-10.  
It is the Vietnam War that brought significant public attention to this emotional disorder.  In 
1980, PTSD was recognized as a disorder by the American Psychiatric Association (APA) 
and was added to the Diagnostic Manual of Mental Disorders (DSM). In fact, before PTSD 
was recognized as an emotional disorder, it was considered to be  nothing more than 
cowardice or personal weakness1.  
PTSD also has one or more comorbidities. These common co-morbid diagnoses include 
major affective disorders (MDD), bipolar disorder, dysthymia, alcohol or substance abuse 
disorders, anxiety disorders and personality disorders. The mechanisms underlying the 
high rate of co-morbidity seen with PTSD are still unknown. There are no exclusionary 
criteria in DSM-III-R. Diagnostic criteria for PTSD include a history of exposure to a 
"traumatic event" and symptoms from each of three symptom clusters: intrusive 
recollections, avoidant/numbing and hyper arousal symptoms. Duration of symptoms is 
considered as a fifth criterion. The following are the common symptoms - a three-factor 
PTSD structure in the DSM system.  
4. Current studies of PTSD symptom models and diagnosis 
Although the PTSD symptoms of three-factor (re-experience, avoidance/numb, and hyper-
arousal) has been considered as the diagnostic categories in the DSM system, several studies 
found  three factors to be insufficient2 and proposed several alternative models. In 1998, 
King et al3 proposed a model of four-factor, which comprises re-experience, avoidance, 
emotional numbing, and hyper-arousal by separating the Avoidance/Numbing factor into 
two factors: Avoidance and Emotional Numbing. Their studies are supported by other 
groups, which conducted the factor analysis4-6 .  
Simms et al7 proposed another four-factor model in 2002. Their model includes re-
experiencing, avoidance, dysphoria, and hyper-arousal. The difference between their model 
and King’s model is that they separated hyper-arousal symptoms into a larger dysphoria 
factor as a non-specific PTSD component, representing a general level of distress6-12. It is 
possible that different models can be used for analyzing different data sets6. For example, 
the model proposed by Simms et al7 may be useful for analysis of the PTSD Checklist (PCL) 
data13, while the model proposed by King et al3 may analyze the Clinician Administered 
PTSD Scale14. Currently, it is still a challenge to determine the symptom structure of PTSD in 
the DMS system.   
The current PTSD criteria miss several reactions that many trauma survivors experience. 
There is a new study suggesting that the current diagnostic procedures for PTSD are 
insufficient15. The study believes that some items need to be added in the current criteria 
including the nature of a traumatic event to reflect the relevancy of an individual’s 
subjective experience in determining what constitutes a traumatic event15 and claims that 
both objective and subjective factors are relevant. They report that individuals adapt to 
extreme experiences in a highly complex and coordinated manner. Trauma response is 
multifaceted and includes appraisals and thoughts, emotions and behaviors.  However, it is 
difficult to quantify an experience whether it is traumatic objectively. Individual variation is 
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induced by many factors. Thus, trauma or not trauma is an individual matter, interaction 
between the individual and his or her environment, and all parts of an individual’s 
response. Since PTSD is a traumatic event associated disease, understanding how to define a 
traumatic experience is critical. It is suggested to add more appropriate criteria to more 
accurately categorize traumatic events. Knowing exactly what trauma is can help us to 
better understand who is a trauma survivor and who is not. Therefore, it is critical to keep 
this in our mind for the purposes of understanding the disorder and resilience, which has 
been shown in those who are survivors of trauma. 
5. Research of quantification of PTSD symptoms 
The PTSD diagnostic criteria have been revised several times in the DSM system. The 
current diagnostic criterion for PTSD is the DSM system 16. In the DSM-IV-TR (2000), the 
diagnostic criteria (A-F) are specified below. Diagnostic criteria of DSM-IV-TR for PTSD 
include a history of exposure to a traumatic event, meeting two criteria and symptoms from 
each of three symptom clusters: intrusive recollections, avoidant/numbing symptoms, and 
hyper-arousal symptoms.  A fifth criterion is duration of symptoms and a sixth assesses 
functioning. 
5.1 The DSM-IV-TR
16
 
Criterion A: stressor 
The person has been exposed to a traumatic event in which both of the following have been 
present: 
1. The person has experienced, witnessed, or been confronted with an event or events that 
involve actual or threatened death or serious injury, or a threat to the physical integrity 
of oneself or others. 
2. The person's response involved intense fear, helplessness, or horror. Note: in children, it 
may be expressed instead by disorganized or agitated behavior. 
Criterion B: intrusive recollection 
The traumatic event is persistently re-experienced in at least one of the following ways: 
1. Recurrent and intrusive distressing recollections of the event, including images, 
thoughts, or perceptions. Note: in young children, repetitive play may occur in which 
themes or aspects of the trauma are expressed. 
2. Recurrent distressing dreams of the event. Note: in children, there may be frightening 
dreams without recognizable content. 
3. Acting or feeling as if the traumatic event were recurring (includes a sense of reliving 
the experience, illusions, hallucinations, and dissociative flashback episodes, including 
those that occur upon awakening or when intoxicated). Note: in children, trauma-
specific reenactment may occur. 
4. Intense psychological distress at exposure to internal or external cues that symbolize or 
resemble an aspect of the traumatic event. 
5. Physiologic reactivity upon exposure to internal or external cues that symbolize or 
resemble an aspect of the traumatic event. 
Criterion C: avoidance/numbing 
Persistent avoidance of stimuli associated with the trauma and numbing of general 
responsiveness (not present before the trauma), as indicated by at least three of the following: 
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1. Efforts to avoid thoughts, feelings, or conversations associated with the trauma 
2. Efforts to avoid activities, places, or people that arouse recollections of the trauma 
3. Inability to recall an important aspect of the trauma 
4. Markedly diminished interest or participation in significant activities 
5. Feeling of detachment or estrangement from others 
6. Restricted range of affect (e.g., unable to have loving feelings) 
7. Sense of foreshortened future (e.g., does not expect to have a career, marriage, children, 
or a normal life span). 
Criterion D: hyper-arousal 
Persistent symptoms of increasing arousal (not present before the trauma), indicated by at 
least two of the following: 
1. Difficulty falling or staying asleep 
2. Irritability or outbursts of anger 
3. Difficulty concentrating 
4. Hyper-vigilance 
5. Exaggerated startle response 
Criterion E: duration 
Duration of the disturbance (symptoms in B, C, and D) is more than one month. 
Criterion F: functional significance 
The disturbance causes clinically significant distress or impairment in social, occupational, 
or other important areas of functioning. 
Specify if: 
Acute: if duration of symptoms is less than three months 
Chronic: if duration of symptoms is three months or more 
Specify if: 
With or without delay onset: Onset of symptoms at least six months after the stressor 
In the DSM system, the "A" stressor criterion specifies that a person has been exposed to a 
catastrophic event involving actual or threatened death or injury, or a threat to the physical 
integrity. Subjects experience intense fear, helplessness, or horror, during the traumatic 
exposure. In the "E" stressor criterion, it is duration, which qualifies for the (chronic or 
delayed) PTSD diagnosis. For example, in DSM-III, the mandatory duration is six months. In 
DSM-III-R, the duration is one month, where it has remained in DSM-IV. Finally, the 
functional significance criterion (F) indicates that the subject must have significant social, 
occupational, or other distress as a result of these symptoms. 
Since 1980, the first time the diagnosis of PTSD appeared in the DSM system, many diagnostic 
tools have been developed. For example, working with Vietnam War zone veterans, both 
psychometric and psychophysiology assessing techniques were developed. In addition, 
modified assessment instruments have been used in many research subjects, such as the 
natural disaster victims, rape/incest survivors, subjects of Sept. 11 and the military personnel 
who deployed to Iraq and Afghanistan wars.   
Several methods have been used in quantification and assessing of PTSD symptoms, 
including the Clinician-Administered PTSD Scale (CAPS)14 and the PTSD Checklist (PCL)13. 
The CAPS is a structured interview for assessing PTSD (PTSD diagnostic status and 
symptom severity. In the last 20 years, since it was developed at the National Center for 
PTSD, the CAPS has become a commonly used criterion to determine PTSD and its 
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symptom severity. More than 200 studies used it, indicating its excellent reliability, yielding 
consistent scores across items, raters, and testing occasions. It also has excellent convergent 
and discriminate validity, diagnostic utility, and sensitivity to clinical change. The CAPS has 
been used in many pharmacological treatment studies of PTSD, and modified as CAPS-2. 
Using CAPS-2 to examine the therapeutic response, Nagy et al17 and van der Kolk et al18 
report that fluoxetine significantly decreased CAPS-2 total score. Katz et al19 and Baker et 
al20 also use the CAPS to examine patients’ response to brofaromine. Hertzberg et al21 and 
Busuttil et al22 used the CAPS to examine inpatient group therapy. However, there are 
several concerns about the CAPS. First, it may take longer on paper than other PTSD 
interviews. Second, it may be complicated and not easy to learn. Finally, its frequency and 
intensity ratings overlap.  The CAPS has been revised several times with the most significant 
revision occurring after the publication of the DSM-IV in 1994. It is suggested that CAPS 
diagnostic ability would be enhanced by incorporation of a multimodal assessment.  
Currently, in general, CAPS has been used as a screening instrument and as a self-report 
measure of degree of post-traumatic stress symptoms23. 
Several other self-report inventories, such as Foa24 and Davidson's Self-Rating PTSD Scale25  
and the older Impact of Events Scale26  also have been used in PTSD research. Among them, 
Impact of Events Scale - Revised (IES-R) has been commonly used in research. IES-R is a 22-
item self-report measure to assess subjective distress caused by traumatic events26. It contains 
seven additional items related to the hyper-arousal symptoms of PTSD. Its items correspond to 
14 of the 17 DSM-IV symptoms of PTSD. It is to identify a specific stressful life event and then 
indicate how much the patient was distressed or bothered during the past seven days. Each of 
items is rated on a five-point scale ranging from 0 ("not at all") to 4 ("extremely"). The total 
score (ranging from 0 to 88) and subscale scores can also be calculated for the intrusion, 
avoidance, and hyper-arousal subscales. It is suggested to use means instead of raw sums for 
each of these subscales scores to allow comparison with scores from the Symptom Checklist 90 
– Revised (SCL-90-R)27. While the IES-R is not used to diagnosis PTSD, it is reported that its 
cutoff scores can be applied in a preliminary diagnosis of PTSD. 
6. Brain imaging and magnetoencephalography (MEG) in PTSD research  
Brain image, such as functional magnetic resonance imaging (fMRI), has enhanced our 
ability to examine the structural and functional properties of the brain in PTSD.  Several 
lines of evidences demonstrate that fMRI and magnetoencephalography (MEG) can be used 
for PTSD diagnosis and monitoring   therapeutic responses. In an fMRI study, Yin et al 
report  that PTSD patients show decreased amplitude of low-frequency fluctuation (ALFF) 
values in right lingual gyrus, cuneus, middle occipital gyrus, insula, and cerebellum, and 
increased ALFF values in right medial and middle frontal gyri, relative to traumatized 
individuals without PTSD28. The ALFF value in the right medial frontal gyrus is positively 
correlated with severity of the disorder. To examine how the function of brain changes 
during the recovery from PTSD, PTSD patients underwent  two fMRI scans, 6-9 months 
apart, while viewing fearful and neutral faces in preparation for a memory test 
(administered outside the scanner). At the second scan, 65% of patients were in remission 
and their current symptom levels correlated positively with memory-related fMRI activity 
in the amygdala and ventral-medial prefrontal cortex (vmPFC). The change in activity of 
hippocampus and the subgenual anterior cingulate cortex (sgACC) is associated with the 
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degree of symptom improvement. These data indicate that differential brain regions within 
the fear network play different roles in symptom manifestation and in recovery from PTSD. 
The amygdala and vmPFC appear to be specific brain regions having the activity to serve as 
a marker for current symptom severity, while the functional changes in the hippocampus 
and sgACC may be a marker for recovery29. Meanwhile it is also found that there is greater 
recruitment and coupling of emotional brain regions during the retrieval of negatively 
intense autobiographical memory  in the PTSD group when compared to controls30. PTSD 
patients have less activation to the threat condition and increased activity to the safe 
condition in the subgenual cingulate, ventral striatum and extended amygdala, as well as in 
midbrain periaquaeductal grey. These data indicate abnormal reactivity in these key regions 
for fear expression. The temporal pattern of activity decrease found in control subjects was 
not obtained in PTSD patients31. Imaging analyses also find decrease of activity in the 
amygdala and hippocampus of PTSD patients during successful encoding of trauma-related 
stimuli. Such decrease in left hippocampus is associated with high arousal symptoms. These 
results indicate  reduction of  hippocampal activity under conditions of high stress and 
arousal32. Significant improvements of PTSD are evident on fMRI scans, and corroborated 
by Clinical Global Impression (CGI) scores, but CAPS scores improvements are modest, 
indicating CGI scores and fMRI scans can be used to examine the improvement of PTSD. 
Patients with child abuse-related complex PTSD show reductions in gray matter levels in 
right hippocampus, right dorsal ACC and the right orbitofrontal cortex (OFC) compared to 
controls. Meanwhile their child abuse and hyper-arousal correlated negatively with ACC 
volume. Impulsivity and anger correlated negatively with hippocampus volume, and OFC 
volume respectively. In another study, it is found that PTSD is associated with smaller mean 
cornu ammonis 3 (CA3)/dentate gyrus subfield volumes and total hippocampal volume, 
indicating that PTSD is associated CA3 implying that chronic stress suppresses 
neurogenesis and dendritic branching in this structure33. As in adult PTSD, children with 
symptoms of post-traumatic stress suffer poor function of the hippocampus, exhibiting 
more errors on the recall part of the test and showing less hippocampus activity than control 
subjects doing the same task34. 
MEG, a test that measures magnetic fluctuations faster as groups of neurons fire (neither CT 
scans nor MRIs can measure it), has been used for PTSD diagnosis. The MEG is cutting edge, 
but it's not new technology. It has been used since the late 1960s. Perhaps best of all, the 
mapping of synchronous neural interactions (SNI) works regardless of what the person being 
observed is doing. Recently one study shows that PTSD patients demonstrate a unique pattern 
of miscommunication. The PTSD patients show impaired. A 50-ms response (M50) gating in 
the right hemisphere. Thinner right superior temporal gyrus (STG) cortical thickness is 
associated with worse right sensory gating in the PTSD subjects. The right primary sensory 
cortex (S1) M50 source strength and gating ratio is correlated with PTSD symptomatology. 
These findings indicate that the structural integrity of right hemisphere STG cortices play an 
important role in auditory sensory gating deficits in PTSD35. It is found that the SNI test which 
assesses the functional interactions among neural populations derived from MEG recordings36 
can successfully differentiate PTSD patients from healthy control subjects. 
7. Complications of PTSD 
Individuals with PTSD are 8–14 times more likely to have a second lifetime diagnosis of 
psychosis after the development of PTSD, with 50–80% of those being affective and anxiety 
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disorders37. PTSD is more common among depressed primary care patients than previously 
thought, and 62% of individuals diagnosed with PTSD have suicidal ideation38. Here we 
discuss several common mental disorders seen in PTSD patients, such as alcohol and drug 
abuse, and depression. 
7.1 PTSD and alcohol and drug abuse 
People with PTSD are more likely than others of similar background to have alcohol use 
disorders both before and after being diagnosed with PTSD. For example, 25-75% and 10-
33%of survivors of abusive or violent trauma, accidental illness, or disaster trauma have 
problematic alcohol use, respectively.  60-80% of Vietnam veterans seeking PTSD 
treatment have alcohol use disorders. Veterans over the age of 65 with PTSD have 
increased risk for attempted suicide if they experience problematic alcohol use or 
depression. Those survivors with alcohol problems have ongoing health problems or pain. 
In addition, there is gender difference in drinking. Women who go through trauma have 
more risk for drinking problems.  27.9% of women with a history of PTSD report 
problems with alcohol abuse or dependence at some point in their Lifetime. Almost twice 
as many men (51.9%) with a history of PTSD reported such problems. As a point of 
comparison, Kessler and colleagues find that, on average, 24.75% of men and 10.55% of 
women without PTSD have problems with alcohol or drugs at some point in their lifetime. 
Alcohol use and intoxication, and suddenly stopping drinking can result in some 
symptoms worse, including avoidance, anger, irritability and depression. Suddenly stop 
drinking can also result in worsening of some the symptoms. In addition to alcohol, the 
consistent findings demonstrate that patients with PTSD have a high risk of drug use.  For 
example, 34.5% of men and 26.9% of woman with PTSD also have a problem with drug 
abuse or dependence during their lifetime.   
7.2 PTSD and depression 
Depression is one of the most frequent comorbid conditions in individuals with PTSD. In 
fact, 48% of subjects with PTSD also have current or past depression. Individuals with PTSD 
are almost seven times as likely as individuals without PTSD to have depression. 44.5% of 
individuals with PTSD one month after experiencing a traumatic event have a diagnosis of 
depression39-42. 
7.3 PTSD and anxiety  
Like PTSD and depression, there is a strong relationship between PTSD and anxiety 
disorders. Patients with PTSD are more likely to have anxiety disorders. Around 7% of 
patients with PTSD at some point in their life also have had a diagnosis of Panic Disorder. 
Patients with PTSD are four times as likely to also have a current or past diagnosis of Panic 
Disorder as compared to non-PTSD control. Approximately 28% of patients with PTSD have 
or have had a diagnosis of Social Anxiety Disorder. Patients with PTSD are three times as 
likely as someone without PTSD to have Social Anxiety Disorder. It has been found that 4% 
to 22% of patients with PTSD also have obsessive-compulsive disorder (OCD). Finally there 
are strong relationships between PTSD and other anxiety disorders, such as phobia. Over 
30% of patients with PTSD had or have had a specific phobia. Patients with PTSD are seven 
times as likely as people without a history of PTSD to have also had a specific phobia. 
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7.4 PTSD and traumatic brain injury (TBI) 
Since the war in Iraq and Afghanistan, PTSD and TBI were significantly increased in the 
military service members. PTSD and TBI are comorbid. Patients with both PTSD and TBI 
exhibit a spectrum of common clinical features such as difficulty in concentrating, sleep 
disturbance, depression, anxiety, irritability, fatigue, suicidality, chronic pain, and 
alterations in arousal.  PTSD and TBI disorders have overlapping neural mechanisms with 
changes in hippocampal, prefrontal cortical and limbic region function because of 
alterations in synaptogenesis, dendritic remodeling, and neurogenesis. These neural 
changes in PTSD and TBI may result from pathophysiological disturbances in metabolic, 
cytotoxic, inflammatory, and apoptotic processes, amongst other mechanisms43.  
7.5 PTSD and metabolic syndrome 
Several lines of research suggest that stress and post-stress adaptation responses are related 
to long-term health outcomes. Studies of survivors of disasters, veterans and prisoners of 
war, and others exposed to severe trauma, suggest higher rates of physical morbidity and 
mortality and increased healthcare utilization related to lifetime prevalence of trauma. 
Accumulating evidence from epidemiological studies demonstrate that chronic PTSD 
associated with trauma and secondary negative health outcomes including metabolic 
conditions. 43% of PTSD met criteria for metabolic syndrome, indicating that PTSD is 
associated with risk factors for diminished health and increased morbidity, as represented 
by metabolic syndrome. 
7.6 PTSD and pain 
The co-occurrence of PTSD and chronic pain symptoms have been observed clinically.  For 
example, it is found that 10% of patients referred to a Veterans Administration pain clinic 
meet criteria for PTSD and that 9.5% of patients attending a multidisciplinary chronic pain 
center meet criteria for "post-traumatic pain syndrome"44. In the patients who are referred 
for the assessment of a chronic pain problem resulting from a traumatic event, the 
prevalence of PTSD is also high. Hospitalized burn patients have high rates of PTSD at 12 
months post-injury45. 80% of PTSD patients report the presence of a chronic pain condition. 
In addition, PTSD re-experiencing symptoms were positively associated with pain level and 
pain-related disability. The co-occurrence of chronic pain and PTSD may have implications 
in terms of an individual's experience of both conditions. Patients with chronic pain related 
to trauma or PTSD experience more intense pain and affective distress46, higher levels of life 
interference47, and greater disability than pain patients without trauma or PTSD48, 49. The 
most common forms of chronic pain for survivors of trauma are pain in the pelvis, lower 
back, face and bladder; and in fibromyalgia; interstitial cystitis; and non-remitting Whiplash 
syndromes. However, the relationship between PTSD and chronic pain  is not always 
noticed and is often overlooked50, 51. Both PTSD and chronic pain can increase the symptom 
severity of either condition52.  Patients with chronic pain may focus their attention toward 
their pain while individuals with PTSD may unknowingly focus on things that remind them 
of the trauma. Consequently, both PTSD and chronic pain may result in patients having less 
time and energy to adapt their pain and fear. Furthermore, patients with PTSD often have 
hyper-arousal and tension, which may interference their perception of pain. Patients with 
co-morbid pain and PTSD demonstrate more intense pain, more emotional distress, higher 
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levels of life interference, and greater disability than pain patients without PTSD. Treating 
these patients can also be more complex and challenging. 
Currently, the mechanism for the co-occurrence of PTSD and pain is still unknown. There 
are several theoretical models, such as mutual maintenance model51, shared vulnerability 
model50, fear-avoidance model  and triple vulnerability model53.  However, those models 
needed to be tested.  
7.7 PTSD and other diseases 
The association of traumatic life events with PTSD and other health conditions is well 
known. For example, patients with PTSD had substantially higher (i.e., 50–150% greater) 
postwar rates of many major chronic diseases, including circulatory, nervous system, 
digestive, musculoskeletal, and respiratory diseases54. PTSD is significantly associated with 
an almost two-fold increase of developing nervous system, musculoskeletal disease, and 
signs and ill-defined conditions of disease. PTSD is significantly associated with increased 
odds of developing circulatory, hypertensive, and digestive system disease55.  More data 
shows that PTSD patients have abnormally high white blood cell counts (>11,000/mm3) and 
T-cell counts (>2,640/mm3)56. 
Evidence linking exposure to traumatic stress and cardiovascular disease is compelling. 25% 
of PTSD veterans report physician-diagnosed circulatory diseases (vs. 13% for PTSD 
negative veteransIt is also reported that PTSD veterans are significantly more likely to have 
had abnormal electrocardiograph (ECG) results (28% vs. 14%) with a higher prevalence of 
myocardial infarctions and atrioventricular conduction defects57. There are positive 
association between chronic PTSD and myocardial infarction (MI) as well as lower plasma 
levels of high-density lipoprotein-cholesterol (HDL-C)54, 57, 58. In a population study 
involving World War II and Korean War veterans, it is found higher rates of physician-
diagnosed cardiovascular disease among PTSD subjects59. Another study among Dutch 
resistance fighters demonstrate increased rates of cardiovascular disease risk factors among 
PTSD60. A large-scale civilian population study also found an increase in ischemic heart 
disease among adults exposed to childhood traumas61. Furthermore, adults exposed to the 
Chernobyl disaster have increased rates of reported heart disease62. In addition, studies 
during the Beirut Civil War and the Croatia War find increases in arteriographically 
confirmed coronary heart disease, cardiovascular disease mortality, and increases in acute 
myocardial infarction (AMI) associated with exposure to these conflicts63, 64. An increase in 
AMIs is also reported after the Hanshin-Awaki earthquake in Japan64. 
Evidence indicates that exposure to environmental stressors and subsequent development of 
PTSD may be related to altered neuroendocrine and immune system functions, and the 
onset of specific immunoendocrine-related diseases. Either increases or decreases of 
circulating cortisol levels in PTSD patients are reported. The former indicates an acute 
response or up-regulated glucocorticoid system, while later suggesting a chronic or 
downregulated glucocorticoid system. Either direction of these changes may result in an 
alteration activities of immune inflammatory. Indeed. glucocorticoids influence the 
trafficking of circulating leukocytes and affect functions of leukocyte and immune accessory 
cells. Hyper-arousal is often observed during recollection of traumatic events by PTSD 
victims and is associated with alterations in the neuroendocrine functions. Although these 
processes are complex, chronicity and excessiveness of stress system activation in PTSD 
could be one possible pathogenesis, which is associated with weight loss, depression, 
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hypogonadism, immunosuppression, and other pathophysiological conditions leading to 
many diseases. Therefore, the research in these specific areas is demanded and emphasized 
to improve the quality of life of patient with PTSD65.   
8. Treatment of PTSD 
There are many therapeutic methods for treatment of PTSD, including cognitive-behavioral 
therapy (CBT) and medication. In clinical study, it is reported that combinations of exposure 
therapy and cognitive restructuring as well as CBT produces better therapeutic response, 
especially in the treatment of female victims of childhood or adult sexual trauma.   
The first FDA approved group of compounds for PTSD are selective serotonin reuptake 
inhibitors (SSRIs), including sertraline (Zoloft) and paroxetine (Paxil). In addition, there is a 
report showing that Eye Movement Desensitization and Reprocessing (EMDR) may have 
better therapeutic response as well.   
Dr. Friedman suggests that mildly to moderately affected PTSD patients may need group 
therapy (http://www.veterans.gc.ca/eng/sub.cfm?source=mental-health/support/factsshc). 
In this therapeutic approach, the PTSD patient is asked to discuss their traumatic memories, 
PTSD symptoms, and functional deficits. However, since PTSD is a chronic and severely 
debilitating psychiatric disorder, there is no better approach yet. New ideas and approaches 
need to be developed. The following is a brief summary of current available approaches for 
treatment of PTSD.  
Currently, several psychotherapies have been used in clinical practice, including CBT, 
exposure therapy, stress inoculation training (SIT), cognitive restructuring, and EMDR. CBT 
has been shown to be the most effective type of therapeutic treatment. CBT helps to 
recognize and change inaccurate thoughts about subjects. Exposure therapy is the best 
technique for recovery, involving overcoming anxieties by facing them in a controlled and 
safe environment and relieving fears all at once (flooding) or step-by-step (desensitization) 
in order to overcome them. Although this may seem frightening at first, this treatment 
produces a quick outcome. Supportive counseling, without facing the trauma, has also been 
shown to be helpful, but may not be as effective as direct exposure. The SIT consists of 
teaching the PTSD subjects to manage their anxiety reactions to situations, memories, etc. 
they normally fear and avoid. For the physical manifestations of anxiety (heart rate, 
hyperventilation, and muscle tension). The SIT teaches controlled breathing and progressive 
muscle relaxation. For intrusive thoughts and worrying, The SIT teaches patients how to 
interrupt their thought patterns and think of positive imagery. By this way, the PTSD can 
control and lessen their PTSD symptoms.  
The other therapy is cognitive restructuring, which helps subjects identify and challenge 
their erroneous beliefs and interpretations. It is based on the idea that it is not actual events 
that cause negative emotional reaction but the interpretation of those events, letting to the 
replace worry and anxiety with more positive and productive emotions.  
In addition, EMDR allows the therapist to have the PTSD patients remember their trauma 
briefly and then engage in cognitive restructuring. 
In recent years, several alternative therapies have been introduced in PTSD treatment, 
although its effectiveness is still need to be determined. They are included in massage, 
acupuncture, art and music therapy, drama therapy and exercise.  
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8.1 Prognosis 
The best outcome, or prognosis, depends on how soon the symptoms develop after the 
trauma, and on how quickly the patient is diagnosed and treated. 
9. Biomarker research in PTSD 
The term biomarker (biological marker) was first described in 1989 as a substance used as an 
indicator of a biological state. It refers to a Medical Subject Heading term: ‘‘measurable and 
quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone 
concentration, specific gene phenotype distribution in a population, presence of biological 
substances) which serve as indices for health- and physiology-related assessments, such as 
disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, 
metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic 
studies, etc”. In 2001, a definition of a biomarker was described by an NIH working group 
as ‘‘a characteristic that is objectively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention” (NIH Biomarker Definitions Working Group, 2001). In 2004, FDA announced 
that quantitative measures of biological effects that provide informative links between 
mechanism of action and clinical effectiveness are considered to be biomarkers (FDA 
whitepaper ‘Innovation or Stagnation’ 2004). The World Health Organization (WHO) 
defines the biomarker as any substance, structure or process that can be measured in the 
body or its products and can influence or predict the incidence or outcome of disease (WHO 
International Program on Chemical Safety).  
Biomarker researches progressed significantly during the 1990s. Since then, the whole field 
of biomarker research has been drastically changed by the human genome project. The 
information gained from the human genome project redirected biomarker studies into a 
whole new era. High-throughput analytical instruments have been used to screen thousands 
of genes and proteins simultaneously. Today, biomarkers have been classified into four 
subgroups including type 0 biomarker, type 1 biomarker, surrogate end point-type (type 2 
biomarker) and risk marker. 
 
Type 0 biomarker: A marker of the natural history of a disease and correlates 
longitudinally with known clinical indices.
Type I biomarker: A marker that captures the effects of a therapeutic intervention in 
accordance with its mechanism of action.
Surrogate end point (type 2 biomarker): A marker that is intended to substitute for a 
clinical end point; a surrogate end point is expected to predict clinical benefit (or harm or 
lack of benefit or harm) on the basis of epidemiological, therapeutic, pathophysiological, or 
other scientific evidence.
Risk marker. For prevention, the important disease risk factors are those that can be 
measured quantitatively in the subject at risk. These factors can be used to identify cohorts 
for prevention. Those may also be used as endpoints in prevention studies. 
 
Table 1. Identification of Biomarkers 
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9.1 Potential biomarker(s) for PTSD 
High-throughput “omic” approaches including genomics, proteomics, and metabolomics 
have been used in candidate biomarker selection and identification for many diseases66 
(Table 2). However, progress of the search for PTSD biomarkers has been slow and often 
frustrating because the complexity of the molecular mechanisms of the disease and the 
undefined validation process. Potential biomarker(s) for PTSD on the basis of animal 
research67 or limited studies in humans have been proposed. But confirmation and 
validation of their clinical utility have not been accomplished. Appropriate and efficient 
validation would be expedited with valid animal models, standardized laboratory practice, 
larger human population-based studies, and repeated sampling of individuals. A strategy 
used in biomarker development for other illnesses68  can also be used for development of  a 
blood biomarker test for PTSD. Here, we will discuss the strategy including screening 
approach as well as analytical and clinical validations to facilitate PTSD blood biomarker 
discovery and selection. 
 
Technology Method Test 
Genomics 
SNP genotyping 
Susceptibility or disease 
modifying gene 
Positional 
cloning/microsatellites 
Fine mapping/sequencing of 
disease loci 
Microarray Gene expression 
Proteomics 
2DGE, MS, LC-MS, GC-MS, MS-
MS, MALDI-TOF MS 
Protein expression 
Metabolomics 
NMR spectroscopy, MS, 
infrared spectroscopy 
Small molecule 
Table 2. Biological tools are used in screening PTSD biomarker  
In the case of PTSD, to screen the potential biomarkers, researchers currently compare the 
gene and protein expression profiles or alteration of a gene, protein expression or metabolite 
levels between PTSD patients and healthy control subjects by using several well developed 
procedures (Table 1).  Biomarkers may be obtained from saliva, blood, cerebral spinal cord 
fluid, urine and tissues. It also can be physiological parameters such as blood pressure69, 
ECG70, and hart betting71, transmitters, such as 5-HT72, dopamine73 and GABA74 or their 
metabolites, and brain-imaging75. Biomarkers indicate PTSD or PTSD characteristics, 
including the level or type response of exposure to a traumatic stress, genetic susceptibility, 
genetic responses to traumatic stress exposure, markers of subclinical or clinical state, or 
indicators of response to therapy. These markers may dynamically alter during the course of 
PTSD development or differentially change after single or multiple traumatic stresses, 
respectively (Table 3).   
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Potential biomarker  References 
T cell phenotypes Lemieux A, Coe CL, Carnes M. 2008 76 
Assumptions Rosen GM, Lilienfeld SO. 2008 77 
Erythrocyte sedimentation rate, white blood 
cell count, and cortisol/ 
dehydroepiandrosterone-sulfate ratio 
Boscarino JA 2008 78 
Endothelial dysfunction in plasma von Känel R, 2008 79 
Serum interleukin-2 and interleukin-8 levels Song et al. 2007 80 
Platelet serotonin concentration  
Kovacic Z et al., 2008 72 
Pivac N, et al., 2006 81 
Mück-Seler D, et al., 2003 82 
Spivak B, et al., 1999 83 
Platelet MAO-B activity Pivac, N et al., 2007 84 
Circulating Cortisol levels 
Meewisse ML et al., 2007 85 
Ehlert  U et al.,  2001 86 Heber R, et al., 
2002 87 
Glover DA, Poland RE, et al., 2002 88 
Yehuda R, et al., 2002 89 
Glucocorticoid receptor (GCR) expression in 
lymphocyte 
Gotovac K, et al., 2003 90 
WFS1 gene Kesner Y et al, 2007 91 
Baseline level of platelet-leukocyte aggregates, 
platelet CD63 expression, and soluble P-
selectin concentration 
Vidović A et al.,  2007 92 
GABA plasma levels Vaiva G et al.. 2006 93 
S-100B and neuron-specific enolase Sojka P et al., 2006 94 
NPY expression 
Dutton MA, Lee EW, Zukowska Z. 
2006 95 
Myelin basic protein Wang Q, et al., 2004 96 
C-reactive protein and serum amyloid A Söndergaard HP, et al., 2004 97 
Urinary dopamine Glover DA, et al. 2003 88 
Thyroid hormone  Garrison RL, Breeding PC. 2003 98 
Neopterin Atmaca M, et al., 2003 99 
Plasma and cerebrospinal fluid interleukin-6 
concentrations 
Barker DG, et al., 2002 100 
Maes M, et al., 1999 101 
REM latency 
Reist C, et al., 1995 102 
Kauffman CD et al, 1987 103 
Average heart rate responses to a series of 
sudden, loud-tone presentations 
Pitman RK, et al., 2006 104 
Bryant RA. Et al., 2007 105 
Mixed lateral preference and parental left-
handedness 
Chemtob CM, Taylor KB, 2003 106 
Startle responses Milde AM, et al., 2003 107 
Table 3. Potential Biomarkers for PTSD 
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PTSD biomarkers can be the indicators of PTSD trait (risk factor or risk marker), disease 
state (preclinical or clinical), or disease rate (progression). The PTSD biomarkers in all 
possible respects: antecedent, screening, diagnostic, staging and prognosis are listed in 
Table 4.  
 
Biomarkers Function or indicator 
Antecedent 
Identifying the risk of developing PTSD, changes in response to 
single or multiple traumatic stress events 
Screening 
Subclinical PTSD from well adapted subjects, physiological 
responding 
Diagnostic Recognizing PTSD 
Staging Categorizing PTSD severity 
Prognostic Predicting PTSD course: recurrence and response to treatment 
Table 4. Types of biomarker for PTSD 
PTSD biomarker(s) may prove to be a single biological parameter associated with a highly 
specific symptom or a multiple biological indicator (cluster) related to multiple symptoms. 
Individual biomarkers have been shown to be a significant predictor of PTSD occurrences. 
Few studies have evaluated the use of multiple biomarkers for patient risk stratification67. 
The assessment of multiple biomarkers67 may be useful for identifying subgroups of PTSD  
that would benefit most from additional testing.   
The desirable properties of biomarkers for PTSD vary with their different usage. For 
example, a screening test may be used in large populations including normal and high-risk 
subjects. Thus, the biomarker requires having high sensitivity, specificity, and predictive 
values, large likelihood ratios, and low cost.  A diagnostic biomarker should be appropriate 
for use at any stages of the disease (acute and chronic) and have consistent detectability in 
patients at any stage of illness or treatment. For biomarkers to be used in monitoring PTSD 
progression or response to therapy, features such as sensitivity or specificity may be less 
important because the patient serves as his or her own control (baseline values are 
compared with follow-up values). The ability to monitor intra-individual variation as this 
relates to clinical status is more important. Costs may be less important for prognostic 
markers since only people with PTSD will be tested. Searching for prognostic PTSD 
biomarkers may be most challenging because it requires a larger sample and prospective 
design, whereas a diagnostic biomarker test requires relatively smaller sample size and a 
cross-sectional design. While all the features of biomarkers can be combined in one for a 
screening test, having specific features for specific use is the ultimate goal in the search for 
PTSD biomarkers. It would be ideal to have a biomarker that can differentiate the three 
conditions (physiological response, well adapted and acute PTSD) in the early traumatic 
stages. The overall benefit of a PTSD biomarker would be to enhance the ability of the 
clinician to optimally manage the patient with PTSD, and to help the researcher and 
clinician identify specific therapeutic targets. For instance, an EEG test may be expected to 
facilitate the identification of patients with sleep problems. A biomarker such as the level of 
glucocorticoid108 and/or concentration of epinephrine in the blood may help to differentiate 
subjects who have transient acute response to traumatic stress from patients who ultimately 
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develop PTSD. A plasma GABA level may represent a marker of recovery from trauma93. In 
general, a biomarker test for PTSD should be not only accurate, reproducible, and 
standardized, but also acceptable to PTSD patients and easy-to-use for clinicians.  
9.2 A strategy to identify a PTSD biomarker  
Like studies of biomarkers in other medical fields, the strategy for identification of a PTSD 
biomarker includes three major steps: screening, analytical validation and clinical validation 
(Fig 1). 
 
 
Fig. 1. A strategy searching for a PTSD biomarker 
9.2.1 Screening a biomarker(s) for PTSD 
Currently, many biological tools have been used for screening potential PTSD biomarkers 
(Table 2). Biomarker screening is the first step in identifying a potential PTSD biomarker. 
During the screening stage, animal models have been used. However, the complexity and 
variability of PTSD symptoms make the establishment of generally validated animal models 
for biomarker screening more challenge67. The most current animal models use different 
stress paradigms to provoke a wide range of behavioral responses. In addition, results have 
been presented as mean values (with SD or SE) of the entire exposed population. These 
animal models may overlook the clinical finding that only a proportion of individuals (20%–
30%) who are exposed to a "traumatic event" will eventually develop PTSD67. Therefore, 
multi-dimensional validation, such as a combination of both behavioral and biological 
criteria, may be necessary to provide a solid basis for the biomarker screening study and for 
the molecular mechanism research67.  
Compared to other psychiatric and medical illnesses relatively little work has been directed 
toward elucidating the molecular mechanisms of posttraumatic psychopathology. There are 
some association studies for individual molecular targets, but these are inherently limited to 
hypothesis–driven search for candidates already implicated through the current framework of 
biological theorizing. Previously, the possibility of identifying molecular targets for PTSD in a 
genome-wide screen in a validated animal model using microarray gene expression profile 
analysis have been discussed67. The mRNA levels of p11, a member of the S-100 protein family, 
increase in the post mortem prefrontal cortex (area 46) of PTSD patients109. Stress, induced by 
three days of inescapable shock, increases both p11 mRNA levels in the prefrontal cortex (PFC) 
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of rats and corticosterone levels in plasma. Dexamethasone (Dex), a synthetic glucocorticoid, 
up-regulates p11 expression in SH-SY5Y cells through glucocorticoid response elements 
(GREs) within the p11 promoter, which can be attenuated by either a glucocorticoid receptor 
antagonist, RU486, or mutating two of the three glucocorticoid response elements (GRE2 and 
GRE3) in the p11 promoter. This work demonstrates not only an example of a study of 
mechanisms of posttraumatic psychopathology, but also identification of a potential PTSD 
biomarker, p11. Also, mitochondrial gene expression profiling in post-mortem brain of 
patients with PTSD110 serves as a source of biomarkers. The study emphasizes the possible 
molecular mechanisms for PTSD, the analytical validation of sample purity, large scale 
scanning and cluster classification.   Obtaining pure samples for genomic analysis requires 
highly stringent criteria and should be validated along three dimensions—analogous 
(similarity of behavior), predictive (predictability of drug response) and biological mechanism 
(gene expression). Analytical validation should also be considered.   
9.2.2 Analytical validation for a PTSD biomarker(s) 
Although several candidate biomarkers for PTSD have been identified by screening 
approaches, few have been validated81, 93, 108, 111. Meaningful validation requires high-
throughput bioinformatics and large sets of data. In addition to statistical validation and 
biological/functional validation, analytical validations may be more important and have to 
be completed prior to their use in clinical sites.  In 1999, the United States Food and Drug 
Administration established a final guidance for the industry validation of analytical 
procedures and terminology112,113. This document provides guidance on characteristics for 
consideration during the validation of analytical procedures. This guidance represents 
current thinking about validation. According to this guideline, analytical validation include 
the following aspects: precision (reproducibility), accuracy (clinical samples; compare to 
cleared or gold standard method), limit of detection, potential interferences software, sample 
preparation/conditions, performance around the cut-off, potential for carryover or cross-
hybridization and assay limitations. Obviously, the guideline can be used for analytical 
validation of PTSD biomarkers. In this guideline many concepts or terms were defined.  We 
review several major terms related to PTSD biomarker development here.  First is precision. In 
the guideline, precision was defined as reproducibility, which requires that intended users 
using clinical samples and all analytical steps of the assay get reliable results; User training 
should be the same for studies and for marketed assay.  Precision is considered at three major 
levels: repeatability, intermediate precision and reproducibility. Repeatability expresses the 
precision under the same operating conditions over a short interval of time and is also termed 
intra-assay precision.  Intermediate precision expresses within laboratory variations (different 
days, different analysts, different equipment, etc).  Reproducibility expresses the precision 
between laboratories (collaborative studies, usually applied to standardization of 
methodology) and is assessed by means of an inter-laboratory trial.  
The second term that we discuss here is accuracy. The accuracy of an analytical procedure 
expresses the closeness of agreement between the value, which is accepted either as a 
conventional true value or an accepted reference value. Accuracy requires the use of real 
clinical samples; to compare to a reference method; in limited cases (i.e., very rare alleles) 
contrived samples can be used; samples should mimic the molecular composition and 
concentration of real clinical samples. This is sometimes termed ‘trueness’. 
The third term is the detection limit. The detection limit is determined by the analysis of 
samples with known concentrations of analyte and by establishing the minimum level at 
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which the analyte can be reliably detected. The detection limit of an analytical procedure is 
the lowest value of analyte in a sample. The maker can be detected but not necessarily 
quantitated as an exact value. Visual evaluation can be used for non-instrumental methods 
but may also be used with instrumental methods. Signal-to-noise with-this approach can 
only be applied to analytical procedures which exhibit baseline noise. The signal-to-noise 
ratio can be determined by comparing measured signals from samples with known low 
concentrations of analyte with those of blank samples. A signal-to-noise ratio between 3 or 
2:1 is generally considered acceptable for estimating the detection limit.  
It is also noticed that in the screening stage, microarray has emerged as an important format 
for simultaneous analysis of tens of thousands of substances present in a sample. Successful 
adaptation of microarray assays to clinical diagnostics will require particular attention to 
issues of quality control and quality assurance. Results of an assay can be compromised by a 
number of pre-analytical factors including the quality of the reagents (e.g., the microarray 
and the detection reagents) and the integrity of the sample. Similarly, numerous factors in 
the analytical phase of a microarray assay may compromise results, including changes in the 
reaction conditions and calibration. Furthermore, a microarray study combines many 
reagents or samples in a single device. This process brings additional confounds not usually 
encountered in discrete testing of a single analysis in a single sample. Thus, various 
strategies, such as replicate analysis and normalization have to be implemented to control 
and assess analytical factors in these studies. The current range of measures taken to ensure 
the analytical accuracy and quality of data generated from proteomics and metabolomics 
assays in other fields may also be applied in the context of DNA microarrays. Taking 
everything together, the data have to be documented with analytical validation for each of 
the operator and instrument prior to clinical validation.  
9.2.3 Clinical validation for PTSD biomarkers   
As a newly discovered biomarker assay makes the transition from a research setting to the 
clinical diagnostic laboratory, it should progress through defined stages of assay 
confirmation. At the screening stage, a validation focused on evaluation of research assay 
technology, performance, and specifications (analytical validation) is most important. 
However, the ultimate goal is validation of the test ability to identify PTSD.  Assays have to 
be developed into final procedures that are standardized and reproducible for clinical 
diagnostic implementation. Thus, the final step of development of PTSD biomarker should 
be clinical validation (clinical utility).  
Clinical validation or clinical utility will be based on new clinical trial data. These clinical 
data should be prospectively collected in a longitudinal study with appropriate institutional 
review board (IRB) and informed consent. These clinical samples must be well 
characterized. They will show clinical utility in prospective clinical studies and retrospective 
validation. Clinical and analytical cut-off points should be described and independently 
validated.  Clinical cut-off points should be identified in a training set and validated in a test 
set. Clinical cut-offs can reference data from literature. Bridging studies are required if a 
platform change or device change is necessary after clinical validation.  
For markers of clinical status, clinical validation refers to measurement of how biomarker 
level is related to a change in the clinical status of a patient114. The changes are not compared 
only with the average normal, but to the patient’s own baseline values obtained when they 
are first diagnosed with the same procedure. The dynamic changes of the biomarker value 
in the same patient indicate the inherent variability of the data. The variability can be due in 
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part to the reproducibility of the analytical measurement, but also due to natural 
physiological changes or PTSD progression. Therefore longitudinal study of a control 
(healthy) population may be needed to determine the extent to which level changes 
represent biological variability rather than changes in disease status. In addition, to 
determine the relationship of biomarker alteration between peripheral and contral nervous 
system (CNS) could be more important in clinical validation study for PTSD.  We found that 
biomarkers in the brain and in the blood are not necessarily altered in the same direction.  
Finally, the validity of the biomarker test, including its rates of false negatives and false 
positives should be well-established before the tests enter clinical use.  
Currently, the diagnosis for PTSD is based on a certain set of symptoms determined from 
the patient’s clinical history, mental status examination, duration of symptoms, and clinician 
administered symptom checklists or the patient self-report. However, there are no available 
laboratory biomarker tests for PTSD. To begin intervention at the earliest possible time, 
priority must be given to developing objective approaches to determine the presence of 
PTSD. Thus, a simple blood test or a biomarker that could detect PTSD in its earliest and 
potentially most treatable stages would be beneficial for physicians and patients. Currently, 
many potential biomarkers have been identified in animal models and in patients with 
PTSD. But those biomarkers have not been well validated. Current strategy to identify a 
biomarker for PTSD involves pre-clinical screening, analytical validations and clinical 
validations. This strategy will enhance not only the study of the molecular mechanisms of 
PTSD, but also the translation of basic science to clinical implications. 
During the last decade, with the rise of genomics and advances in molecular biology, 
researchers have become increasingly focused on the underlying molecular mechanisms of 
PTSD and searching for a biomarker for PTSD. New technologies have the potential to 
identify PTSD biomarkers in blood to definitively diagnose patients with PTSD or to 
identify those who may be at high risk for developing PTSD after traumatic exposure. The 
development of such biomarker tests requires a strategy that involves pre-clinical screening, 
analytical validations and clinical validations, and is driven by the advances in research 
surrounding the underlying molecular mechanisms of PTSD (Fig 1). 
The first potential PTSD biomarker has been discovered. In 2009, we reported that p11 
mRNA expression is significantly changed in post mortem cortex of patients with PTSD and 
depression, and in their peripheral blood mononuclear cells (PBMC). We hypothesize that 
p11 mRNA levels in the peripheral blood cells can serve as a biomarker for PTSD with 
heterogeneity in terms of type of trauma, time since trauma and duration of illness. We 
examined the PBMC p11 mRNA of patients with PTSD (n = 13), major depressive disorder 
(MDD, n = 16), bipolar disorder (BP, n = 24), and schizophrenia (SCZ, n = 12) or controls (n 
= 14) using quantitative real-time PCR and the circulating levels of cortisol in blood plasma 
and saliva of PTSD patients using radioimmunoassay kit CORT-CT2. The Hamilton Rating 
Scale for Depression (HAMD) and Anxiety (HARS), the Chinese version of the Davidson 
Trauma Scale- Frequency (CDTS-F) and the Chinese version of the Davidson Trauma Scale-
Severity (CDTS-S), and Impact of Event Scale-Revised (IES-R) were administered. We found 
that patients with PTSD had lower levels of p11 mRNA than control subjects, while those 
with MDD, BP and SCZ had significantly higher p11 levels than the controls. P11 mRNA 
levels were positively correlated with the scores of HAMD (r = 0.62, p < 0.05), CDTS-F (r = 
0.71, p < 0.05) and CDTS-S (r = 0.62, p < 0.05), while they did not correlate with scores of 
HARS and IES-R. Basal levels of plasma and salivary cortisol of PTSD patients were not 
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statistically different from those of controls. Our findings suggest that PBMC p11 mRNA 
expression levels may serve as a biomarker to distinguish PTSD from BP, MDD and SCZ.  
 
 
 
 
Fig. 2. Significantly lower p11 mRNA levels in the patients with PTSD compared to control 
and other mental disorders. BP, Bipolar, MDD, Major depressive disorder, SCZ, 
schizophrenia.  
In the table 5, we summarized potential biomarkers in gene association studies. 
 
Gene Methods Results Reference 
Serotonin 
transporter 
Association analysis 
The low-expression variant 
(short allele) modifies risk of 
PTSD.
115-119 
Cytomegaloviro
us gene (CMV) 
Methylation microarrays to 
assay CpG sites from more 
than 14,000 genes, among 23 
PTSD-affected and 77 
PTSD-unaffected 
individuals.
CMV-a typically latent herpes 
virus whose activity was 
significantly higher among those 
with PTSD. 
120 
FK506 binding 
protein 5 
(FKBP5) 
1143 European Americans 
(EAs) and 1284 African 
Americans (AAs), screened 
for lifetime PTSD. 4 SNPs in 
FKBP5, rs3800373, 
rs9296158, rs1360780, and 
rs9470080, were genotyped. 
In AAs, one of the SNPs, 
rs9470080, moderated the risk of 
PTSD that was associated with 
childhood abuse 
121 
www.intechopen.com
 
Anxiety Disorders 
 
88
Catechol-o-
methyltransfera
se  (COMT) 
(Val158Met) 
Association analysis in 424 
survivors of the Rwandan 
Genocide. 
Met/Met homozygotes 
exhibited a high risk for PTSD 
independently of the severity of 
traumatic load.
122 
Dopamine beta-
hydroxylase 
(DBH) 
(1021C/T) 
Association analysis in 
combat veterans with (N = 
133) or without (N = 34) 
chronic PTSD.
A significantly lower plasma 
DBH activity in combat veterans 
with PTSD carrying the CC 
genotype 
123 
Interleukin-2 
(IL-2) 
Interleukin-8 
(IL-8) 
34 earthquake survivors 
with PTSD (according to 
DSM-IV criteria), 30 
earthquake survivors with 
non-PTSD and 34 controls 
in northern China 
Earthquake survivors with 
PTSD had significantly lower 
serum IL-8 levels. PTSD may be 
associated with a reduced level 
of serum IL-8, and traumatic 
survivors may be associated 
with a lower level of serum IL-2. 
80 
C-reactive 
protein 
3049 adults living in the 
community (Germany). 
CRP, lipoproteins and 
triglycerides determined. 
Also examined blood 
pressure, body mass index 
(BMI), physical activity, 
comorbid somatic diseases, 
medication, daily alcohol 
intake, and depression. 
PTSD positive participants 
significantly higher odds for 
elevated CRP values than those 
without PTSD (OR=2.27; 95% CI: 
1.32-3.93). Even after adjusting 
for sex, age, other 
sociodemographic factors, BMI, 
blood pressure, lipoproteins and 
triglycerides, physical activity, 
comorbid somatic diseases, 
daily alcohol intake, and trauma 
exposure, almost two-fold 
higher odds for elevated CRP 
levels in participants with PTSD. 
124 
NPY qPCR, SNP, western blot 
Low cerebrospinal fluid NPY 
plasma concentrations
125-127 
P11 
Real time PCR, PTSD post-
mortem brain and blood 
cells
P11 over-expressed in the CNS 
and down-regulated in the 
blood
109, 128 
Table 5. Association studies: genotype and symptoms - endophenotype  
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